This indicates that measuring the expression of these 48 genes in addition to standard NB diagnosis and risk assessment could be beneficial for predicting therapy efficacy, especially for stage 4 tumors without MYCN amplification. The gene discussed is MYCN; the disease is neuroblastoma.